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ABSTRACT Since high-affinity adenosine A2 receptors
(A2u) are localized exclusively in dopamine-rich regions in the
central nervous system and mediate inhibition of locomotor
activity, we have examined the effect of A2 receptor activation
on D1 and D2 receptor binding in membrane preparations of
the rat striatum. The A2a agonist 2-p-(2-carboxyethyl)phen-
ethylaminoJ-5'-N-ethylcarboxamidoadenosine (CGS 21680)
increased the Kd of the dopamine D2 agonist L-(-)-N-
[3H]propylnorapomorphine without affecting the Be.. The
increase in Kd was maximal (40%) at 30 nM CGS 21680. CGS
21680 (30 nM) decreased the dopamine-induced inhibition of
PH]raclopride (a D2 antagonist) binding due to an increase
(about 3-fold) in KH and KL, the dissociation constants of high-
and low-affinity binding sites. The effects of CGS 21680 were
antagonized by the adenosine antagonist 8-phenyltheophyfline
(10 pM). (-)-N6-(2-Phenylisopropyl)adenosine produced an
effect similar to that ofCGS 21680, provided the concentration
used was high enough to stimulate A2 receptors (300 nM). GTP
(50 pAM) also decreased the dopamine-induced inhibition of
PHlraclopride binding but, in contrast to CGS 21680, GTP
decreased the proportion of D2 receptors in the high-affinity
state. CGS 21680 (30 nM) did not affect the Kd or Bm. of[3Hlraclopride and failed to affect ligand binding to D1 recep-
tors. Thus, stimulation of A21 receptors potently reduces the
affinity ofD2 agonist binding sites within the plasma membrane
of striatal neurons. This A2,-D2 interaction may underlie the
neuroleptic-like actions of adenosine agonists and the enhanc-
ing effects of adenosine antagonists, such as caffeine, on
locomotor activity.
Adenosine has been shown to function as a neuromodulator
in many areas of the mammalian central nervous system
(1-3). These actions of adenosine are mediated by receptors
that can be subdivided into Al and A2 subtypes based on
relative agonist and antagonist potencies (4, 5). Al activation
inhibits and A2 activation stimulates adenylate cyclase (4, 6,
7). The A2 receptors have been further subclassified into
high-affinity (A2a) and low-affinity (A2b) receptors, based on
agonist potencies with regard to adenylate cyclase activation
(4) and receptor binding (5). The A2b receptors are widely
distributed in the brain and mediate the stimulatory action of
high concentrations of adenosine agonists on cAMP forma-
tion, which could affect dopamine release and synthesis (8,
9). In contrast, A2a receptors are exclusively localized to
dopamine-innervated areas ofthe central nervous system (10,
11), with a postsynaptic distribution (12) similar to that of
postsynaptic D1 and D2 receptors (13). By using in situ
hybridization the recently cloned A2a receptors (14) have
been found to be localized to striatal medium-sized neurons
(15).
Adenosine agonists inhibit, whereas adenosine antago-
nists, including caffeine, enhance spontaneous (16, 17) and
dopamine-induced locomotor activity (16, 18-20). The po-
tencies of adenosine agonists in producing hypomotility
correlate with their affinities for Au adenosine receptors (21,
22), suggesting that A2. receptors mediate most of the be-
havioral effects of adenosine agonists. The hypomotility
induced by adenosine agonists resembles that induced by
classical neuroleptics (22), which act by blocking postsyn-
aptic D2 receptors (23). In fact, behavioral evidence for a
negative interaction between postsynaptic A2. and D2 recep-
tors has recently been obtained using acutely reserpinized
mice (24, 25). Since activation of postsynaptic D2 receptors
seems to be a necessary step for locomotor behavior, a
negative interaction between postsynaptic A2. and D2 recep-
tors could explain the hypomotility induced by adenosine
agonists and the enhancement of locomotor activity induced
by adenosine antagonists, including caffeine (24, 25).
In contrast to the A2a receptor, the D2 receptor mediates an
inhibition of adenylate cyclase (26). However, the stimula-
tory activity of A2a receptors on adenylate cyclase cannot
simply explain the counteractive action of A2a stimulation on
D2-mediated locomotor activity since D, receptors, which
also stimulate adenylate cyclase, potentiate D2-mediated
locomotor activity (24). One possibility could be the exis-
tence of a more direct interaction between A2a and D2
receptors. Earlier studies have shown that L-glutamate (27),
SCH 23390 (28), and neuropeptides such as neurotensin
(29-31, 44) and cholecystokinins 4 and -8 (32) can modulate
the binding characteristics of striatal %2 agonist binding sites
by means of intramembrane interactions. To investigate the
existence of an intramembrane interaction between A2a and
D2 receptors, we have examined whether adenosine analogs
such as the recently developed selective A2a agonist 2-[p-(2-
carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoaden-
osine (CGS 21680) (33-35) can modulate the binding charac-
teristics of dopamine D2 receptors in membrane preparations
of rat striatum. It was found that, in rat striatal membranes,
the stimulation of A2a receptors decreases the affinity of D2
agonist binding.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (body weight, 200-
250 g; Alab, Stockholm) were kept under regular lighting
conditions (lights on at 06:00 and off at 20:00) in a tempera-
Abbreviations: CGS 21680, 2-[p-(2-carboxyethyl)phenethylamino]-
5'-N-ethylcarboxamidoadenosine; NPA, L-(-)-N-propylnorapo-
morphine; R-PIA, (-)-N6-(2-phenylisopropyl)adenosine; 8-PT,
8-phenyltheophylline; SCH 23390, (R)-(+)-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochlo-
ride.
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ture-controlled environment and had free access to food
pellets and tap water. The rats were decapitated with a
guilliotine, and the brain was rapidly removed and placed on
ice. The brain was partially cut in the midline and the
neostriatum was removed with a sharp forceps.
Saturation Experments with L-(-)-N-[3HJPropylnorapo-
morphine ((3INPA). The tissue was weighed, introduced in
polypropylene vials, and sonicated for 30 s in ice-cold
Tris HCl buffer (50 mM, pH 7.6) containing 0.01% L-(+)-
ascorbic acid and 1 mM EDTA. Tris buffer (as above) was
added and the homogenate was centrifuged for 10 min at
45,000 x g (Sorvall SS-34 rotor; RC-SB centrifuge, DuPont
Instruments, Sorvall Division). The supernatant was dis-
carded and the membrane pellet was resuspended by soni-
cation in Tris buffer and preincubated for 30 min at 370C. This
preincubation was followed by another centrifugation for 10
min at 45,000 x g. The pellet was resuspended in Tris buffer
(final concentration of membranes, 2.5 mg of wet weight per
0.5 ml of incubation medium), and saturation curves with 10
concentrations (0.05-2 nM) of the D2 agonist [3H]NPA (2.0
TBq/mmol; NEN) (30) were determined by incubation for 30
min at 250C with or without the presence of the various drugs
under study [CGS 21680, 8-phenyltheophylline (8-PT), GTP].
Nonspecific binding was defined as the binding in the pres-
ence of raclopride (1 ,uM) (Astra Lakemedel, S6dertilje,
Sweden) (36). The incubation was stopped by washing the
membranes three times with 5 ml of ice-cold Tris buffer over
a Whatman GF/B filter (Millipore) under reduced pressure.
The radioactivity content of the filters was detected by liquid
scintillation spectroscopy. Protein contents were determined
with bovine serum albumin as a standard (37).
Saturation Experiments with [3H]Radopride. The tissue
was prepared as described above, in the same buffer as for[3H]NPA binding but also including MgCl2 (5 mM). Satura-
tion experiments with 10 concentrations (0.5-15 nM) were
performed by incubation with [3H]raclopride (1.5 TBq/
mmol, Astra Lakemedel, Sodertdlje, Sweden) (36) for 30 min
at room temperature in the presence or absence of CGS
21680. Nonspecific binding was defined as the binding in the
presence of (+)-butaclamol (1 ,uM).
Competition Experiments with Dopamine Versus PHJRaclo-
pride. The tissue was prepared as in saturation experiments
with [3H]raclopride. Competitive inhibition experiments with
20 single concentrations (10 pM-l mM) of dopamine were
performed by incubation with 2 nM [3H]raclopride for 30 min
at room temperature in the presence or absence of the
different drugs under study [CGS 21680, 8-PT, GTP, (-)-N6-
(2-phenylisopropyl)adenosine (R-PIA)].
Competition Experiments with Dopamine Versus (R)-(+)-7-
Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-lH-3-[N-methyl-3Hibenzazepine Hydrochloride, (pHISCH 23390).
The tissue was prepared as described above, but without the
preincubation, in 50 mM Tris HCl buffer (pH 7.4) containing
120 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 1 mM MgCl2.
Competition experiments with 20 concentrations (10 pM-1
mM) of dopamine were performed by incubating the mem-
branes with [3H]SCH 23390 (2.6 TBq/mmol; NEN) (38) for 15
min at 37°C in the presence or absence of the different drugs
under study (CGS 21680, GTP).
Data Analysis. Data from saturation experiments were
analyzed by nonlinear regression analysis of the raw data for
the determination of Kd and B values using a computer
program kindly provided by Stdphane Swillens (Institut de
Recherche Interdisciplinaire, Universite Libre de Bruxelles,
Campus Erasme, Brussels, Belgium). Linear fitting of Scat-
chard plots from the same data yielded similar estimates.
Data from competition experiments were analyzed by the
LIGAND program (39). The specific binding and affinity for
each affinity state were determined by computerized nonlin-
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FIG. 1. Effect of increasing concentration of CGS 21680 on Kd
values of [3H]NPA binding in rat striatal membranes. Membranes
were incubated with [3H]NPA and the indicated concentrations of
CGS 21680 alone (-) or in the presence (o) of8-PT (10 A.M) for 30 min
at room temperature. Kd and B.. were calculated by nonlinear
regression from saturation curves using 10 concentrations of[3H]NPA, with raclopride (1 AM) for the determination of nonspe-
cific binding. Data show the mean + SEM of nine separate experi-
ments (four experiments for 8-PT). *P < 0.05 and **P < 0.01 against
control. The B.. values, 193 ± 7, 214 ± 16, and 217 ± 8 fmol/mg
of protein for control, CGS 21680 (30 nM), and 8-PT (10 AM),
respectively, were not significantly affected.
rately. The amount of nonspecific binding (about 0.5% of the
free ligand) was calculated by extrapolation of the displace-
ment curve. Kd, B.., pseudo-Hill coefficients, KH and KL,I
as well as the proportion ofreceptors in the high-affinity state
(RH) were analyzed by Student's paired t test or by single-
factor repeated measures analysis of variance followed by
Fisher's protected least-square difference method. To
achieve homogeneity of variance and allow parametric sta-
tistical analysis, KH and KL values were logarithmically
transformed (40).
RESULTS
Saturation Experiments with [3HJNPA. CGS 21680 (10-100
nM) increased the Kd of [3H]NPA binding sites, without
affecting the B, (Figs. 1 and 2). The increase in Kd was
maximal (about 40%6) at 30 nM CGS 21680 and disappeared
at 300 nM. 8-PT (10 AM), which by itself did not produce any
change in [3H]NPA binding, completely antagonized the
effect of CGS 21680 (Fig. 1). GTP (50 .uM) increased the Kd
of [3HJNPA by 53% ± 17% without significantly affecting the
Be, (data not shown).
Saturation Experiments with [3HJRaclopride. CGS 21680
(30 nM) did not affect the affinity or the density of [3H]ra-
clopride binding sites (4.95 ± 0.49 nM and 360 ± 31 fmol/mg
of protein for control versus 5.06 ± 0.19 nM and 364 ± 25
fmol/mg ofprotein for CGS 21680; four paired experiments).
Competition Experiments with Dopamine Versus PH]Raclo-
pride. Competition curves with dopamine versus [3H]raclo-
pride showed a significantly better fit for two binding sites
than for one (pseudo-Hill coefficient, around 0.5-0.6; data
not shown). CGS 21680 (30 nM but not 300 nM) significantly
decreased the dopamine-induced inhibition of [3H]raclopride
binding, by increasing by about 3-fold KH and KL, without
affecting RH (Fig. 3; Table 1). These increases were com-
pletely antagonized by 8-PT (10 1uM), which by itself did not
produce any changes in KH and KL (Table 1).
1KH and KL are the dissociation constants of high-affinity and
low-affinity binding sites presented as antilogarithms (geometric
mean and 95% confidence limits of the geometric mean) of the
logarithmic-transformed data used for statistical analysis (40).
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FIG. 2. Representative saturation curves showing the effect of
CGS 21680 on [3H]NPA binding in rat striatal membranes. Mem-
branes were incubated with CGS 21680 (30 nM) and [3H]NPA for 30
min at room temperature. The Kd and Bmax were 171 pM and 184
fmol/mg of protein for control (a) and 251 pM and 207 fmol/mg of
protein in the presence of CGS 21680 (a) as calculated by nonlinear
regression using raclopride (1 uM) for the determination of nonspe-
cific binding. (Inset) Corresponding Scatchard plots of the saturation
binding data.
In a concentration that selectively stimulates Al receptors,
R-PIA (3 nM) did not affect the competition curves of
dopamine versus [3H]raclopride. However, in a concentra-
tion that activates A2a receptors (300 nM), R-PIA produced
an -3-fold increase in KH and KL, similar to CGS 21680 at 30
nM, without affecting RH (Table 1).
GTP (50 AM) also decreased the dopamine-induced inhibi-
tion of [3H]raclopride binding but, in contrast to CGS 21680,
GTP reduced RH, without affecting KH or KL (Table 1).
Competition Experiments with Dopamine Versus [3H]SCH
23390. Competition curves with dopamine versus [3H]SCH
23390 showed a significantly better fit for two binding sites
than for one (pseudo-Hill coefficient, around 0.5-0.6; data
not shown). CGS 21680 (30 nM) did not affect the dopamine-
induced inhibition of [3H]SCH 23390 binding, in contrast to
GTP (50 /iM), which decreased RH (Table 2).
DISCUSSION
The present study has shown that stimulation of adenosine
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FIG. 3. Representative competitive-inhibition curves illustrating
the effect of CGS 21680 (30 nM) on dopamine-induced inhibition of
[3H]raclopride binding in rat striatal membranes. By using the
LIGAND program (39), the dissociation constants of high-affinity and
low-affinity D2 agonist binding (KH and KL) were estimated to 3.9 nM
and 148 nM under control conditions and 11.8 nM and 363 nM in the
presence of CGS 21680. The percentage of D2 agonist binding sites
(RH) in the high-affinity state was 65% and 73%, respectively.
D2 agonist binding sites in membrane preparations from rat
striatum. In concentrations at which they act on A2a recep-
tors, CGS 21680 (34, 35) and R-PIA (5, 34) affected KH and
KL of D2 agonist binding sites. The reduced affinity of D2
agonist binding was observed by using the agonist [3H]NPA,
which selectively labels D2 sites under the present conditions
(30), and by displacing the specific D2 antagonist [3H]raclo-
pride with dopamine. The increase in Kd (40%) of [3H]NPA
binding was lower than that observed in KH and KL (about
3-fold) for competition curves with dopamine versus [3H]-
raclopride. One possible explanation for this difference could
be the fact that [3H]NPA binds to the D2 receptor with a very
high affinity and therefore may be less sensitive to possible
conformational changes of the D2 agonist binding site.
The similarity ofaction ofCGS 21680 and ofR-PIA (at high
concentrations), which are structurally dissimilar agonists,
and the fact that the effect of CGS 21680 on the D2 agonist
binding sites was completely antagonized by the adenosine
receptor antagonist 8-PT indicate that the interaction is
mediated by means of A2a receptors and not by competitive
binding to D2 receptors, as is the case for classical neuro-
leptics (23). The A2a-D2 interaction seems to be specific,
since stimulation of Al receptors with R-PIA at a concentra-
tion (3 nM) close to its Kd for Al receptors (5, 34) failed to
affect D2 agonist binding. In addition, stimulation of A2a
receptors with CGS 21680 (30 nM) failed to affect D1 agonist
binding sites.
Neither the affinity of D2 antagonist binding nor the num-
ber of D2 receptors was affected by CGS 21680, suggesting
that it is the agonist binding to D2 that is selectively affected.
At 30 nM, CGS 21680 produced a reduction of D2 agonist
Table 1. Competition experiments with dopamine versus [3H]raclopride
Treatment KH, nM KL, nM RH, % of total
Control 3.00 (2.36-3.81) 265 (232-304) 66.2 ± 3.6
CGS 21680 (30 nM) 11.27 (8.36-15.21)** 977 (604-1581)* 70.8 ± 5.5
+8-PT (10 uM) 2.21 (1.66-2.94) 134 (95-189) 58.9 ± 4.9
8-PT (10 uM) 2.76 (1.75-4.36) 330 (238-456) 70.2 ± 4.0
CGS 21680 (300 nM) 7.05 (6.24-7.96) 340 (289-399) 72.0 + 2.3
R-PIA (3 nM) 5.31 (3.61-7.82) 357 (249-513) 70.7 ± 6.4
R-PIA (300 nM) 12.65 (10.99-14.56)* 1096 (647-1857)** 77.7 ± 3.0
GTP (50 AsM) 1.91 (1.18-3.09) 347 (257-468) 46.6 ± 9.9**
KH and KL are defined in Materials and Methods; the 95% confidence limits of the geometric mean
are given in parentheses. RH is the percentage of total specific binding sites in the high-affinity state
shown as mean ± SEM. Each treatment is represented by four to eight separate experiments.
*P < 0.05 and **P < 0.01 against control.
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Table 2. Competition experiments with dopamine versus
[3H]SCH 23390
RH, % of
Treatment KH, nM KL, nM total
Control 33.9 (28.4-40.4) 1549 (1346-1782) 41.7 ± 4.3
CGS 21680 24.5 (19.4-31.1) 2089 (1982-2203) 44.1 ± 2.2
(30 nM)
GTP (50 ,M) 41.2 (30.5-55.6) 1698 (1584-1905) 9.4 ± 2.2*
See legend to Table 1. Data represent six separate experiments.
*P < 0.05 against control.
binding comparable to that induced by 50,uM GTP. How-
ever, the effect of A2a receptor stimulation on D2 agonist
binding was different from that seen with GTP, which, in
agreement with earlier results, converted some of the high-
affinity binding sites to low-affinity binding sites without
affecting their affinity constants (41, 42). These results sug-
gest that the effect of A2a receptors, which are coupled to G
proteins (11), is mediated by a different mechanism than the
effect of GTP. This mechanism may be similar to the G
protein-independent mechanism mediating the neuroten-
sin-D2 interaction (31, 44), whereas the D1-D2 interaction
seems to involve G proteins (28).
The concentration of CGS 21680 producing the maximal
effect on D2 agonist binding is close to its Kd value for the Au
receptor. This indicates that the maximal effect on Dz agonist
binding is obtained when the A2a receptor is stimulated by
drugs close to their Kd values. At saturating concentrations
of CGS 21680 (300 nM), the D2 agonist binding was not
significantly altered, as seen from the Kd value of [3H]NPA
binding and from the KH and KL of competition curves with
dopamine versus [3H]raclopride. This biphasic concentra-
tion-response curve is similar to that seen with neurotensin
(31, 44) and may be due to a desensitization of the A2
teceptor that is taking place within the plasma membrane or
the exhaustion of some essential endogenous factor. How-
ever, it differs from the monophasic decrease in D2 agonist
binding seen following treatment with neurotensin in vivo (43)
or with direct D2 antagonists.
In conclusion, the present study has revealed that stimu-
lation of A- receptors potently reduces the affinity of D2
agonist binding sites in striatal membranes. This interaction,
which is the strongest receptor-receptor interaction at the
binding site hitherto observed, could explain the neuroleptic-
like effects of adenosine agonists and why adenosine antag-
onists, such as caffeine, enhance locomotor activity.
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